AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Therapeutic vaccination to block receptor-ligand interactions possible.
2003 AUG 13 - (NewsRx.com & NewsRx.net) -- The development of a therapeutic vaccine to block receptor-ligand interactions is possible, say researchers in Switzerland.
According to published research from Switzerland, "Many chronic diseases are caused by non-physiological interactions of certain ligands with their receptors. Conventional treatment of these diseases with synthetic drugs or monoclonal antibodies (mAbs) is efficient, but problematic due to the non-compliance of patients and the risk of adverse side effects.
"Novel therapeutic approaches are focusing on strategies of active immunization aimed at the induction of a humoral immune response directed against the deleterious receptor-ligand interaction."
"Autoantibody production has been achieved by several vaccine formulations, including conjugates of self-antigens to foreign T helper (Th) cell epitopes, virus-like particles coated with self-antigens, and naked DNA vectors," reported Gunther Spohn and Martin F. Bachmann at Cytos Biotechnology AG.
They continued, "All ...
- Cytos Biotechnology AG-Detailed Product Pipeline.
- Press release article from: M2 Presswire March 15, 2009 700+ words
...15 March 2009-www.companiesandmarkets.com: Cytos Biotechnology AG-Detailed Product Pipeline(C)1994-2009 M2 COMMUNICATIONS...www.companiesandmarkets.com adds new report: Cytos Biotechnology AG-Detailed Product Pipeline Pipeline Reports contain detailed...
- Cytos Biotechnology AG-Therapeutic Competitors.
- Press release article from: M2 Presswire January 26, 2009 700+ words
...January 2009-www.companiesandmarkets.com: Cytos Biotechnology AG-Therapeutic Competitors(C)1994-2009 M2 COMMUNICATIONS...www.companiesandmarkets.com adds new report: Cytos Biotechnology AG-Therapeutic Competitors Therapeutic Competitors include...
- Avir Green Hills Biotechnology AG-Company Report.
- Press release article from: M2 Presswire January 21, 2009 700+ words
...2009-www.companiesandmarkets.com: Avir Green Hills Biotechnology AG-Company Report(C)1994-2009 M2 COMMUNICATIONS LTD...companiesandmarkets.com adds new report: Avir Green Hills Biotechnology AG-Company Report Private Company Reports provide up to...
- Cytos Biotechnology AG.
- Newspaper article from: Biomedical Market Newsletter November 30, 2001 700+ words
Cytos Biotechnology AG Dr Claudine Blaser Manager Corporate Development Wagistrasse 21 Postfach Zurich-Schlieren CH-8952 Switzerland 011-41-73...
- US demand for agricultural biotechnology ("ag biotech") products is projected...
- Magazine article from: Research Studies - Freedonia Group January 1, 1999 700+ words
US demand for agricultural biotechnology ("ag biotech") products is projected to increase 27 percent annually to $2.9 billion in the year 2002. While growth will be robust...
- Novartis licenses Cytos' nicotine addiction vacc in deal worth up to 600M...
- Newspaper article from: Pharma Marketletter April 30, 2007 700+ words
Zurich, Switzerland-based Cytos Biotechnology AG has entered into an exclusive global commercial license agreement with Novartis to develop, manufacture and commercialize CYT002...
- Patent rift before court might impact biotechnology, Ag: outcome could limit...
- Magazine article from: San Diego Business Journal Chambers, Heather February 11, 2008 700+ words
A U.S. Supreme Court case testing the limits of a patent holder's rights could spell changes for biotechnology manufacturers and farmers who use genetically engineered products. [ILLUSTRATION OMITTED] At issue in a patent infringement lawsuit involving South Korean electronics maker LG Electronics
- Expert Opinion on Drug Safety Launches an Open-Access Correspondence Section.
- Press release article from: PR Newswire January 6, 2006 700+ words
...regulatory affairs. Over the last year, Expert Opinion on Drug Safety has seen an increase...eds. Published six times a year, Expert Opinion on Drug Safety seeks to unravel the...guides. Each article contains an 'Expert Opinion' section, in which authors are encouraged...
